Hsbc Holdings PLC Has $1.30 Million Stake in Insmed, Inc. $INSM

Hsbc Holdings PLC reduced its position in shares of Insmed, Inc. (NASDAQ:INSM) by 39.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,949 shares of the biopharmaceutical company’s stock after selling 8,474 shares during the period. Hsbc Holdings PLC’s holdings in Insmed were worth $1,304,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of INSM. LPL Financial LLC lifted its stake in Insmed by 56.3% in the 1st quarter. LPL Financial LLC now owns 51,213 shares of the biopharmaceutical company’s stock valued at $3,907,000 after acquiring an additional 18,456 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in shares of Insmed in the first quarter valued at approximately $423,000. Vanguard Group Inc. lifted its position in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Insmed by 3.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,602,655 shares of the biopharmaceutical company’s stock worth $122,267,000 after purchasing an additional 56,048 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in Insmed by 2.6% during the first quarter. Swiss National Bank now owns 329,300 shares of the biopharmaceutical company’s stock worth $25,122,000 after purchasing an additional 8,200 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have issued reports on INSM shares. Cowen reiterated a “buy” rating on shares of Insmed in a research note on Thursday, November 20th. Royal Bank Of Canada raised their price objective on Insmed from $139.00 to $215.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Truist Financial lifted their target price on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. The Goldman Sachs Group increased their price target on Insmed from $196.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Jefferies Financial Group boosted their price target on Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $187.89.

Insiders Place Their Bets

In other news, Director Elizabeth M. Anderson sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares in the company, valued at $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 233,650 shares of company stock worth $41,063,785 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Insmed Trading Down 3.7%

Shares of Insmed stock opened at $196.55 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The business has a fifty day simple moving average of $181.60 and a two-hundred day simple moving average of $136.35. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The company has a market capitalization of $41.92 billion, a price-to-earnings ratio of -31.75 and a beta of 1.01.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. Research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.